Name | BT-11 |
Synonyms | BT11 BT-11 BT 11 Omilancor Methanone, 1,1'-(1,4-piperazinediyl)bis[1-[6-(1H-benzimidazol-2-yl)-2-pyridinyl]- [4-[6-(1~{H}-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1~{H}-benzimidazol-2-yl)pyridin-2-yl]methanone |
CAS | 1912399-75-7 |
Molecular Formula | C30H24N8O2 |
Molar Mass | 528.56 |
Solubility | DMSO: ≥30 mg/mL |
Storage Condition | -20℃ |
In vitro study | In splenocytes isolated from WT or LANCL2 −/− mice, treatment of increasing concentrations of BT-11 and detection of intracellular cAMP levels: BT-11 can stimulate cAMP production by activating the LANCL2 pathway. |
In vivo study | Oral BT-11 of 8 mg/kg/day in mice can slow down the colitis. In the drug safety test in rats, oral administration of high-concentration BT-11 has good safety (detection concentration up to 1000 mg/kg/day). In a mouse model of colitis induced by dextran sulfate sodium, oral administration of BT-11 upregulated the expression level of IL-10 and downregulated the expression of TNF-α mRNA. BT-11 can also upregulate the expression of LANCL2 in the gastrointestinal tract. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.892 ml | 9.46 ml | 18.919 ml |
5 mM | 0.378 ml | 1.892 ml | 3.784 ml |
10 mM | 0.189 ml | 0.946 ml | 1.892 ml |
5 mM | 0.038 ml | 0.189 ml | 0.378 ml |
biological activity | BT-11 is an orally active, C- like 2 (LANCL2) the combined compound, with a Kd value of 7.7 μm, is useful in the treatment of inflammatory bowel disease. |
Target | Value |